{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:27:39Z","timestamp":1787498859663,"version":"build-2736575974"},"reference-count":170,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA257881-01A1"],"award-info":[{"award-number":["P50 CA257881-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of pancreatic cancers and has a very poor prognosis. Ten to 15% are staged as resectable at diagnosis, and 5% to 15% downstaged with therapy to where surgery is feasible. Chemotherapy is a mainstay for all stages of PDAC. Targeted therapies are available for patients with select but expanding actionable genomic alterations. The tumor microenvironment provides a dense stroma with an immunosuppressive milieu that contributes to inherent treatment resistance of PDAC. Herein, we review current management of PDAC with a focus on emerging treatment paradigms, including targeted and immunomodulatory agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>PDAC is a complex disease with unique genomic, immunologic, and clinical features. Recent developments in understanding of the pathobiology of this disease are translating into targeted and immunomodulatory therapies that will alter treatment paradigms and improve outcomes for this recalcitrant malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-25-2014","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:47:38Z","timestamp":1782895658000},"page":"1262-1279","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pancreatic Cancer: Translating Tumor Biology into Actionability"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4703-1560","authenticated-orcid":false,"given":"Fiyinfolu O.","family":"Balogun","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 1 Department of Medicine, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 2 David M. Rubenstein Center for Pancreatic Cancer Research, , New York, New York."},{"name":"3Department of Medicine, Weill Cornell Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7826-3888","authenticated-orcid":false,"given":"Mara H.","family":"Sherman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 2 David M. Rubenstein Center for Pancreatic Cancer Research, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 4 Cancer Biology and Genetics Program, Sloan Kettering Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-3102","authenticated-orcid":false,"given":"Wungki","family":"Park","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 1 Department of Medicine, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 2 David M. Rubenstein Center for Pancreatic Cancer Research, , New York, New York."},{"name":"3Department of Medicine, Weill Cornell Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-017X","authenticated-orcid":false,"given":"Kevin C.","family":"Soares","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 2 David M. Rubenstein Center for Pancreatic Cancer Research, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 5 Department of Surgery, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-146X","authenticated-orcid":false,"given":"Marsha","family":"Reyngold","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 2 David M. Rubenstein Center for Pancreatic Cancer Research, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 6 Department of Radiation Oncology, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3970-9784","authenticated-orcid":false,"given":"Joshua D.","family":"Schoenfeld","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 1 Department of Medicine, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 2 David M. Rubenstein Center for Pancreatic Cancer Research, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8816-0065","authenticated-orcid":false,"given":"Anupriya","family":"Singhal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 1 Department of Medicine, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 2 David M. Rubenstein Center for Pancreatic Cancer Research, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4672-3023","authenticated-orcid":false,"given":"Christine A.","family":"Iacobuzio-Donahue","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 2 David M. Rubenstein Center for Pancreatic Cancer Research, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 7 Department of Pathology and Laboratory Medicine, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-9199","authenticated-orcid":false,"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 1 Department of Medicine, , New York, New York."},{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Memorial Sloan Kettering Cancer Center 2 David M. Rubenstein Center for Pancreatic Cancer Research, , New York, New York."},{"name":"3Department of Medicine, Weill Cornell Medicine, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2026070103130341800_bib1","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"2026070103130341800_bib2","first-page":"1240","article-title":"Pancreatic adenocarcinoma: long-term outcomes of adjuvant therapy in the ESPAC4 phase III trial","volume":"43","author":"Palmer","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib3","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"2026070103130341800_bib4","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO.22.01134","article-title":"Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial","volume":"41","author":"Tempero","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib5","doi-asserted-by":"crossref","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"key":"2026070103130341800_bib6","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib7","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S1470-2045(25)00363-8","article-title":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial","volume":"26","author":"Janssen","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026070103130341800_bib8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070103130341800_bib9","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026070103130341800_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026070103130341800_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070103130341800_bib12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/jnci\/djac018","article-title":"FOLFIRINOX as initial treatment for localized pancreatic adenocarcinoma: a retrospective analysis by the trans-atlantic pancreatic surgery consortium","volume":"114","author":"Janssen","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"2026070103130341800_bib13","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","article-title":"A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)","volume":"181","author":"Ozaka","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026070103130341800_bib15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.6004\/jnccn.2022.7008","article-title":"Neoadjuvant radiotherapy after (m)FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: a TAPS consortium study","volume":"20","author":"Janssen","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2026070103130341800_bib16","doi-asserted-by":"crossref","first-page":"LBA661","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA661","article-title":"NAPOLI-3: a randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil\/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-na\u00efve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)","volume":"41","author":"Wainberg","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib17","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S1470-2045(13)70388-7","article-title":"Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis","volume":"14","author":"Liao","year":"2013","journal-title":"Lancet Oncol"},{"key":"2026070103130341800_bib18","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00000658-199912000-00006","article-title":"Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group","volume":"230","author":"Klinkenbijl","year":"1999","journal-title":"Ann Surg"},{"key":"2026070103130341800_bib19","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2024.42.16_suppl.4005","article-title":"NRG Oncology\/RTOG 0848: results after adjuvant chemotherapy \u00b1 chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA)","volume":"42","author":"Abrams","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib20","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"2026070103130341800_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jamaoncol.2025.0460","article-title":"Nonoperative management of technically resectable pancreatic cancer with ablative radiation therapy","volume":"11","author":"Reyngold","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026070103130341800_bib22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026070103130341800_bib23","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.3390\/cancers15113016","article-title":"Ablative vs. non-ablative radiotherapy in palliating locally advanced pancreatic cancer: a single institution experience and a systematic review of the literature","volume":"15","author":"Kamel","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026070103130341800_bib24","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1200\/JCO-25-00746","article-title":"Tumor treating fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase III PANOVA-3 study","volume":"43","author":"Babiker","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib25","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2026070103130341800_bib26","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"2026070103130341800_bib27","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"2026070103130341800_bib28","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O\u2019Reilly","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib29","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1200\/JCO-25-00436","article-title":"PASS-01: randomized phase II trial of modified FOLFIRINOX versus gemcitabine\/nab-paclitaxel and molecular correlatives for previously untreated metastatic pancreatic cancer","volume":"43","author":"Knox","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib30","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-match trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib31","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026070103130341800_bib32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026070103130341800_bib33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion-positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070103130341800_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026070103130341800_bib37","doi-asserted-by":"crossref","first-page":"EVIDoa2300144","DOI":"10.1056\/EVIDoa2300144","article-title":"Nab-paclitaxel plus gemcitabine and FOLFOX in metastatic pancreatic cancer","volume":"3","author":"Carrato","year":"2024","journal-title":"NEJM Evid"},{"key":"2026070103130341800_bib38","doi-asserted-by":"crossref","first-page":"100318","DOI":"10.1016\/j.esmoop.2021.100318","article-title":"Sequential first-line treatment with nab-paclitaxel\/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial","volume":"6","author":"Assenat","year":"2021","journal-title":"ESMO Open"},{"issue":"16_suppl","key":"2026070103130341800_bib39","doi-asserted-by":"crossref","first-page":"TPS4190","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4190","article-title":"Sequential first-line treatment with gemcitabine plus nab-paclitaxel (GA) followed by FOLFIRINOX (FFX) versus FFX alone in patients with metastatic pancreatic cancer (PC): GABRINOX-2 randomized phase 2 trial","volume":"40","author":"Portales","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"2026070103130341800_bib40","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1200\/JCO.2023.41.16_suppl.4021","article-title":"FOOTPATH: a randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine\/nab-paclitaxel in treatment-na\u00efve metastatic pancreatic cancer (mPDAC)","volume":"41","author":"Westphalen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejso.2016.10.023","article-title":"Radical surgery of oligometastatic pancreatic cancer","volume":"43","author":"Hackert","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"2026070103130341800_bib42","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.3390\/cancers15245881","article-title":"Therapy of locally advanced and oligometastatic pancreatic adenocarcinoma","volume":"15","author":"Wahler","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026070103130341800_bib43","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1200\/JCO.24.00081","article-title":"Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): a multicenter, randomized phase II trial","volume":"42","author":"Ludmir","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib44","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.3390\/cancers14112577","article-title":"Pancreatic ductal adenocarcinoma: current and emerging therapeutic uses of focused ultrasound","volume":"14","author":"Lafond","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026070103130341800_bib45","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00280-018-3650-4","article-title":"Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial","volume":"82","author":"Zhang","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026070103130341800_bib46","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S2468-1253(24)00197-3","article-title":"Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial","volume":"9","author":"Dorman","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026070103130341800_bib47","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib48","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070103130341800_bib49","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","article-title":"Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial","volume":"23","author":"Reiss","year":"2022","journal-title":"Lancet Oncol"},{"issue":"16_suppl","key":"2026070103130341800_bib50","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1200\/JCO.2023.41.16_suppl.4140","article-title":"Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy","volume":"41","author":"Park","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"2026070103130341800_bib51","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/JCO.2025.43.16_suppl.4009","article-title":"Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone after FOLFIRINOX (FFX) induction in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): primary endpoint results of a randomized TEDOPAM GERCOR D17-01 PRODIGE 63 trial","volume":"43","author":"Turpin","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib52","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3748\/wjg.v23.i6.935","article-title":"Familial pancreatic cancer: concept, management and issues","volume":"23","author":"Matsubayashi","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2026070103130341800_bib53","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","volume":"35","author":"Shindo","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib54","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s10147-021-02015-6","article-title":"Hereditary pancreatic cancer","volume":"26","author":"Abe","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"2026070103130341800_bib55","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat Med"},{"key":"2026070103130341800_bib56","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1038\/s41467-020-18613-3","article-title":"Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy","volume":"11","author":"Kato","year":"2020","journal-title":"Nat Commun"},{"key":"2026070103130341800_bib57","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","article-title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","volume":"21","author":"Pishvaian","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026070103130341800_bib58","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","article-title":"GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer","volume":"26","author":"O\u2019Kane","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026070103130341800_bib59","doi-asserted-by":"crossref","first-page":"S898","DOI":"10.1016\/j.annonc.2023.09.2570","article-title":"1621P Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: single-arm RAGNAR trial","volume":"34","author":"Pant","year":"2023","journal-title":"Ann Oncol"},{"key":"2026070103130341800_bib60","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.3390\/cancers15071924","article-title":"Current applications of liquid biopsy in gastrointestinal cancer disease-from early cancer detection to individualized cancer treatment","volume":"15","author":"David","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026070103130341800_bib61","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1002\/cncr.34269","article-title":"Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer","volume":"128","author":"Yu","year":"2022","journal-title":"Cancer"},{"key":"2026070103130341800_bib62","doi-asserted-by":"crossref","first-page":"e145389","DOI":"10.1172\/jci.insight.145389","article-title":"Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients","volume":"6","author":"Wattenberg","year":"2021","journal-title":"JCI Insight"},{"key":"2026070103130341800_bib63","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.3390\/jcm12165394","article-title":"Clinicopathological features and prognosis of resected pancreatic ductal adenocarcinoma patients with claudin-18 overexpression","volume":"12","author":"Park","year":"2023","journal-title":"J Clin Med"},{"key":"2026070103130341800_bib64","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"2026070103130341800_bib65","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"2026070103130341800_bib66","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1158\/0008-5472.CAN-20-0414","article-title":"MTAP deficiency-induced metabolic reprogramming creates a vulnerability to cotargeting de novo purine synthesis and glycolysis in pancreatic cancer","volume":"81","author":"Hu","year":"2021","journal-title":"Cancer Res"},{"key":"2026070103130341800_bib67","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/2159-8290.CD-24-0887","article-title":"AMG 193, a clinical stage MTA-cooperative PRMT5 inhibitor, drives antitumor activity preclinically and in patients with MTAP-deleted cancers","volume":"15","author":"Belmontes","year":"2025","journal-title":"Cancer Discov"},{"key":"2026070103130341800_bib68","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"key":"2026070103130341800_bib69","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/s41467-024-46811-w","article-title":"Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer","volume":"15","author":"Bulle","year":"2024","journal-title":"Nat Commun"},{"key":"2026070103130341800_bib70","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13046-023-02868-x","article-title":"Antibody drug conjugates: hitting the mark in pancreatic cancer?","volume":"42","author":"Wittwer","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"issue":"16_suppl","key":"2026070103130341800_bib71","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2024.42.16_suppl.3002","article-title":"Phase I\/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7_Supplement","key":"2026070103130341800_bib72","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1158\/1538-7445.AM2023-2962","article-title":"Abstract 2962: ASP2138, a novel 2 + 1 format, claudin 18.2 \u00d7 CD3 bispecific antibody, demonstrates selectivity and activity in preclinical cancer models","volume":"83","author":"Nakazawa","year":"2023","journal-title":"Cancer Res"},{"key":"2026070103130341800_bib73","doi-asserted-by":"crossref","first-page":"1773201","DOI":"10.1080\/2162402X.2020.1773201","article-title":"Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients","volume":"9","author":"Lum","year":"2020","journal-title":"Oncoimmunology"},{"issue":"15_suppl","key":"2026070103130341800_bib74","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1200\/JCO.2019.37.15_suppl.4135","article-title":"Clinical and immune responses using anti-CD3 x anti-EGFR bispecific antibody armed T cells (BATs) for locally advanced or metastatic pancreatic cancer","volume":"37","author":"Lum","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib75","doi-asserted-by":"crossref","first-page":"e0294564","DOI":"10.1371\/journal.pone.0294564","article-title":"Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: a phase 2, multicenter, single arm, open label non-randomized study protocol","volume":"18","author":"Karbhari","year":"2023","journal-title":"PLoS One"},{"key":"2026070103130341800_bib76","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp Mol Med"},{"key":"2026070103130341800_bib77","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026070103130341800_bib78","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0092-8674(88)90571-5","article-title":"Most human carcinomas of the exocrine pancreas contain mutant c-K-Ras genes","volume":"53","author":"Almoguera","year":"1988","journal-title":"Cell"},{"key":"2026070103130341800_bib79","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41591-024-03362-3","article-title":"Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival","volume":"31","author":"Varghese","year":"2025","journal-title":"Nat Med"},{"key":"2026070103130341800_bib80","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRASG12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib81","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070103130341800_bib82","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/cac2.70056","article-title":"Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: a pooled analysis of two phase I\/II trials","volume":"45","author":"Li","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"2026070103130341800_bib83","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and structural analysis of common cancer-associated KRAS mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol Cancer Res"},{"key":"2026070103130341800_bib84","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat Med"},{"key":"2026070103130341800_bib85","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.adg9652","article-title":"Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS","volume":"381","author":"Schulze","year":"2023","journal-title":"Science"},{"key":"2026070103130341800_bib86","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/j.annonc.2023.09.1838","article-title":"652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)","volume":"34","author":"Arbour","year":"2023","journal-title":"Ann Oncol"},{"key":"2026070103130341800_bib87","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"2026070103130341800_bib88","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-25-3189","article-title":"A phase II trial of an extended-release siRNA implant targeting KRASG12D\/V in locally advanced pancreatic cancer","volume":"32","author":"Alagesan","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026070103130341800_bib89","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/2159-8290.CD-25-0349","article-title":"Response and resistance to RAS inhibition in cancer","volume":"15","author":"Ebright","year":"2025","journal-title":"Cancer Discov"},{"key":"2026070103130341800_bib90","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"2026070103130341800_bib91","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1200\/JCO.22.02630","article-title":"Nimotuzumab plus gemcitabine for K-Ras wild-type locally advanced or metastatic pancreatic cancer","volume":"41","author":"Qin","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib92","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-23-1313","article-title":"Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma","volume":"83","author":"Gulay","year":"2023","journal-title":"Cancer Res"},{"key":"2026070103130341800_bib93","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","article-title":"BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition","volume":"11","author":"Hofmann","year":"2021","journal-title":"Cancer Discov"},{"key":"2026070103130341800_bib94","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1078-0432.CCR-20-2718","article-title":"Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026070103130341800_bib95","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","article-title":"RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-NF1- and RAS-driven cancers","volume":"20","author":"Nichols","year":"2018","journal-title":"Nat Cell Biol"},{"issue":"16_suppl","key":"2026070103130341800_bib96","doi-asserted-by":"crossref","first-page":"e16403","DOI":"10.1200\/JCO.2025.43.16_suppl.e16403","article-title":"Avutometinib\/defactinib and gemcitabine\/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: updated safety and efficacy of a phase 1b\/2 study (RAMP 205)","volume":"43","author":"Lim","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib97","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"key":"2026070103130341800_bib98","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1158\/2159-8290.CD-24-0740","article-title":"A classical epithelial state drives acute resistance to KRAS inhibition in pancreatic cancer","volume":"14","author":"Singhal","year":"2024","journal-title":"Cancer Discov"},{"key":"2026070103130341800_bib99","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1158\/1078-0432.CCR-24-1164","article-title":"Clinical and genomic features of classical and basal transcriptional subtypes in pancreatic cancer","volume":"30","author":"Singh","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026070103130341800_bib100","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1158\/1078-0432.CCR-22-3930","article-title":"Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer","volume":"29","author":"Singh","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026070103130341800_bib101","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-21-3581","article-title":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","volume":"28","author":"Philip","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026070103130341800_bib102","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/jnci\/djab038","article-title":"Early-onset pancreas cancer: clinical descriptors, genomics, and outcomes","volume":"113","author":"Varghese","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026070103130341800_bib103","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"2026070103130341800_bib104","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/jamaoncol.2016.3916","article-title":"Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma","volume":"3","author":"Connor","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026070103130341800_bib105","doi-asserted-by":"crossref","first-page":"e000578","DOI":"10.1136\/esmoopen-2019-000578","article-title":"Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies","volume":"5","author":"Pokataev","year":"2020","journal-title":"ESMO Open"},{"issue":"16_suppl","key":"2026070103130341800_bib106","doi-asserted-by":"crossref","first-page":"TPS4198","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4198","article-title":"Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1\/2+) pathogenic variants: SWOG S2001","volume":"41","author":"Chung","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib107","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1158\/1078-0432.CCR-23-1467","article-title":"The clinical implications of reversions in patients with advanced pancreatic cancer and pathogenic variants in BRCA1, BRCA2, or PALB2 after progression on rucaparib","volume":"29","author":"Brown","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026070103130341800_bib108","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1158\/1078-0432.CCR-22-3724","article-title":"Comparative genomic analysis of pancreatic acinar cell carcinoma (PACC) and pancreatic ductal adenocarcinoma (PDAC) unveils new actionable genomic aberrations in PACC","volume":"29","author":"Florou","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026070103130341800_bib109","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"2026070103130341800_bib110","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","article-title":"Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer","volume":"21","author":"Whatcott","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026070103130341800_bib111","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s13402-022-00741-1","article-title":"Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment","volume":"46","author":"Zhu","year":"2023","journal-title":"Cell Oncol (Dordr)"},{"key":"2026070103130341800_bib112","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-018-0858-1","article-title":"Tumor microenvironment participates in metastasis of pancreatic cancer","volume":"17","author":"Ren","year":"2018","journal-title":"Mol Cancer"},{"key":"2026070103130341800_bib113","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2026070103130341800_bib114","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.18.01295","article-title":"Phase IB\/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313","volume":"37","author":"Ramanathan","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib115","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","article-title":"HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel\/gemcitabine versus nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma","volume":"36","author":"Hingorani","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib116","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1200\/JCO.2003.02.098","article-title":"Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Moore","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib117","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bjc.6600446","article-title":"A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer","volume":"87","author":"Bramhall","year":"2002","journal-title":"Br J Cancer"},{"key":"2026070103130341800_bib118","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2001.19.15.3447","article-title":"Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial","volume":"19","author":"Bramhall","year":"2001","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib119","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib120","first-page":"44","article-title":"Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer","volume":"26","author":"Hofheinz","year":"2003","journal-title":"Onkologie"},{"key":"2026070103130341800_bib121","first-page":"861","article-title":"Regulation of matrix metalloproteinases - their role in tumor invasion and metastasis","volume":"2","author":"Cottam","year":"1993","journal-title":"Int J Oncol"},{"key":"2026070103130341800_bib122","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.annonc.2021.01.070","article-title":"Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study","volume":"32","author":"Tempero","year":"2021","journal-title":"Ann Oncol"},{"key":"2026070103130341800_bib123","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1158\/1078-0432.CCR-18-4192","article-title":"Dissecting the stromal signaling and regulation of myeloid cells and memory effector T cells in pancreatic cancer","volume":"25","author":"Blair","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026070103130341800_bib124","doi-asserted-by":"crossref","first-page":"20212","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070103130341800_bib125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/pancan.2019.0018","article-title":"Safety and pharmacokinetics of CXCR4 peptide antagonist, LY2510924, in combination with durvalumab in advanced refractory solid tumors","volume":"6","author":"O\u2019Hara","year":"2020","journal-title":"J Pancreat Cancer"},{"key":"2026070103130341800_bib126","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat Med"},{"key":"2026070103130341800_bib127","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/1535-7163.MCT-11-0261","article-title":"Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment","volume":"10","author":"Stokes","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2026070103130341800_bib128","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"2026070103130341800_bib129","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026070103130341800_bib130","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"2026070103130341800_bib131","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1634\/theoncologist.2019-0473","article-title":"Ipilimumab and gemcitabine for advanced pancreatic cancer: a phase Ib study","volume":"25","author":"Kamath","year":"2020","journal-title":"Oncologist"},{"key":"2026070103130341800_bib132","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"2026070103130341800_bib133","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jamaoncol.2024.3651","article-title":"Lynch syndrome and somatic mismatch repair variants in pancreas cancer","volume":"10","author":"O\u2019Connor","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026070103130341800_bib134","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ccell.2018.05.005","article-title":"Selective Fc\u03b3R co-engagement on APCs modulates the activity of therapeutic antibodies targeting T cell antigens","volume":"33","author":"Waight","year":"2018","journal-title":"Cancer Cell"},{"issue":"4_suppl","key":"2026070103130341800_bib135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2025.43.4_suppl.23","article-title":"Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM)","volume":"43","author":"Fakih","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib136","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-21-1345","article-title":"Preclinical characterization and phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB (GEN1046) in patients with advanced refractory solid tumors","volume":"12","author":"Muik","year":"2022","journal-title":"Cancer Discov"},{"key":"2026070103130341800_bib137","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat Med"},{"issue":"8_Supplement","key":"2026070103130341800_bib138","doi-asserted-by":"crossref","first-page":"LB197","DOI":"10.1158\/1538-7445.AM2023-LB197","article-title":"Abstract LB197: a pooled mutant KRAS peptide vaccine activates polyfunctional T cell responses in patients with resected pancreatic cancer","volume":"83","author":"Huff","year":"2023","journal-title":"Cancer Res"},{"key":"2026070103130341800_bib139","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"2026070103130341800_bib140","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"2026070103130341800_bib141","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"key":"2026070103130341800_bib142","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-24-1991","article-title":"First-in-human phase I study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-expressing solid tumors","volume":"31","author":"El-Khoueiry","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026070103130341800_bib143","doi-asserted-by":"crossref","first-page":"eabp9229","DOI":"10.1126\/scitranslmed.abp9229","article-title":"A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors","volume":"15","author":"Melero","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026070103130341800_bib144","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-20-3392","article-title":"Preclinical characterization of HPN536, a trispecific, T-cell-activating protein construct for the treatment of mesothelin-expressing solid tumors","volume":"27","author":"Molloy","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026070103130341800_bib145","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2468-2667(24)00156-7","article-title":"Differences in cancer rates among adults born between 1920 and 1990 in the USA: an analysis of population-based cancer registry data","volume":"9","author":"Sung","year":"2024","journal-title":"Lancet Public Health"},{"key":"2026070103130341800_bib146","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2021.18859","article-title":"Incidence of pancreatic cancer by age and sex in the US, 2000\u20132018","volume":"326","author":"Gaddam","year":"2021","journal-title":"JAMA"},{"key":"2026070103130341800_bib147","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1002\/cncr.24433","article-title":"Pancreatic resection: a key component to reducing racial disparities in pancreatic adenocarcinoma","volume":"115","author":"Murphy","year":"2009","journal-title":"Cancer"},{"key":"2026070103130341800_bib148","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MPA.0000000000000323","article-title":"Pancreatic cancer disparities in African Americans","volume":"44","author":"Khawja","year":"2015","journal-title":"Pancreas"},{"key":"2026070103130341800_bib149","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/cam4.1277","article-title":"Disparities in cancer outcomes across age, sex, and race\/ethnicity among patients with pancreatic cancer","volume":"7","author":"Nipp","year":"2018","journal-title":"Cancer Med"},{"key":"2026070103130341800_bib150","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00432-012-1156-8","article-title":"Racial disparities in treatment for pancreatic cancer and impact on survival: a population-based analysis","volume":"138","author":"Singal","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026070103130341800_bib151","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1089\/heq.2019.0057","article-title":"Disparities in pancreatic cancer treatment and outcomes","volume":"3","author":"Noel","year":"2019","journal-title":"Health Equity"},{"key":"2026070103130341800_bib152","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MPA.0000000000001238","article-title":"Closing the disparity in pancreatic cancer outcomes: a closer look at nonmodifiable factors and their potential use in treatment","volume":"48","author":"Vick","year":"2019","journal-title":"Pancreas"},{"key":"2026070103130341800_bib153","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","article-title":"Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial","volume":"154","author":"Jones","year":"2019","journal-title":"JAMA Surg"},{"key":"2026070103130341800_bib154","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"2026070103130341800_bib155","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib156","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","article-title":"Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer","volume":"27","author":"Cunningham","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib157","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"2026070103130341800_bib158","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.3748\/wjg.v18.i33.4533","article-title":"FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts","volume":"18","author":"Neuzillet","year":"2012","journal-title":"World J Gastroenterol"},{"key":"2026070103130341800_bib159","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/cncr.23810","article-title":"Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer","volume":"113","author":"Xiong","year":"2008","journal-title":"Cancer"},{"key":"2026070103130341800_bib160","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jamaoncol.2019.3394","article-title":"Response rate following albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: a phase 1b\/2 pilot clinical trial","volume":"6","author":"Jameson","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026070103130341800_bib161","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00280-007-0473-0","article-title":"The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis","volume":"61","author":"Fine","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026070103130341800_bib162","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"2026070103130341800_bib163","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026070103130341800_bib164","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"2026070103130341800_bib165","doi-asserted-by":"crossref","first-page":"S787","DOI":"10.1016\/j.annonc.2023.09.2405","article-title":"1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I\/II TRIDENT-1 trial","volume":"34","author":"Solomon","year":"2023","journal-title":"Ann Oncol"},{"key":"2026070103130341800_bib166","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026070103130341800_bib167","doi-asserted-by":"crossref","first-page":"e2341165","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026070103130341800_bib168","doi-asserted-by":"crossref","first-page":"e008872","DOI":"10.1136\/jitc-2024-008872","article-title":"Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","volume":"12","author":"Schenker","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026070103130341800_bib169","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026070103130341800_bib170","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/7\/1262\/3807787\/cd-25-2014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/7\/1262\/3807787\/cd-25-2014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:47:58Z","timestamp":1782895678000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/7\/1262\/786241\/Pancreatic-Cancer-Translating-Tumor-Biology-into"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":170,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-25-2014","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.8568789","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.32845899","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845902","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845911","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845905","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.32845914","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}